Valneva SE

Valneva SE
Societas Europaea
Traded as Euronext: VLA
Industry Biotechnology
Fate established through a merger of former Intercell and Vivalis SA
Founded 2013
Headquarters Lyon, France
Key people
 Thomas Lingelbach (CEO), Frédéric Grimaud (Chairman of the supervisory board)
Products Development of vaccines
Website www.valneva.com

Valneva SE is a fully integrated, commercial stage biotech company focused on developing innovative life-saving vaccines. Valneva was founded in 2013 through the merger of Intercell and Vivalis SA.[1]

It has been listed on the Vienna Stock Exchange and Euronext since May 28, 2013.

Marketed vaccines generated by Valneva include Ixiaro, a vaccine against Japanese encephalitis (approved in Europe, America and Australia)[2] and Dukoral, a vaccine against cholera (approved in Europe, America and Australia)[3]

Some of its candidates have failed in clinical trials: VLA43, a therapeutic vaccine against Pseudomonas Aeruginosa,[4] V710, a therapeutic vaccine against Staphylococcus aureus (in collaboration with Merck),[5] and IC41, therapeutic vaccine against hepatitis C[6]

References

  1. ↑ "Valneva SE company profile, wiener börse". Retrieved 2017-09-02.
  2. ↑ "Ixiaro, Japanese-encephalitis vaccine (inactivated, adsorbed)". European Medicines Agency (EMA). 2009-06-05. Retrieved 2017-04-25.
  3. ↑ "Dukoral, cholera vaccine (inactivated, oral)". European Medicines Agency (EMA). 2009-04-30. Retrieved 2017-04-25.
  4. ↑ "Valneva writes off hospital-acquired infection vaccine following PhII/III miss". FierceBiotech, Questex LLC. 2016-09-01. Retrieved 2017-04-25.
  5. ↑ "Merck ends trial of Intercell's MRSA vaccine". Reuters. 2011-06-08. Retrieved 2017-04-25.
  6. ↑ "Intercell Hepatitis C Vaccine Meets Primary Endpoints". FDA News. 2007-08-22. Retrieved 2008-08-15.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.